Opko Chile S.a., Pharmaceutical Import Profile — Chile (DGFT 2022–2026)

Name: Opko Chile S.a., Pharmaceutical Import Records from India — 7 Products, $11.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Opko Chile S.a., — Pharmaceutical Importer Profile (2026) | 7 Products, $11.2M Trade | TransData Nexus

Opko Chile S.a.,

Pharmaceutical Importer · Chile · Cardiovascular Focus · $11.2M Total Trade · DGFT Verified

Opko Chile S.a., is a pharmaceutical importer based in Chile with a total trade value of $11.2M across 7 products in 4 therapeutic categories. Based on 295 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Opko Chile S.a., sources from 11 verified Indian suppliers, with Emil Pharmaceutical Industries Private Limited accounting for 53.6% of imports.

Opko Chile S.a., — Import Portfolio & Supplier Network

Opko Chile S.a., import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Opko Chile S.a.,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Emil Pharmaceutical Industries Private Limited	$5.3M	165	53.6%
Baroque Pharmaceuticals Private Limited	$1.7M	42	17.1%
Sanpras Healthcare Private Limited

What Formulations Does Opko Chile S.a., Import?

Formulation	Value	Ships
Sertralina 50MG x 500 comp. sertraline tablets 50 MG lic no.mh/drugs/25-kd/276packing:50 x	$280.1K	8
Sertralina 50mgx500 comp. sertraline TAB	$213.2K	6
Omeprazol 20mgx250 capsulas beemil	$192.5K	7
Omeprazol 20MG x 250 capsulas be emilomeprazole capsules 20 MG manufacturing lic.no.mh/drugs/25-kd/276pkg	$189.6K	7
Tramadol 100MG ML gotas frco 10 ML x 20 qty 9000 Box 20x10ml	$150.0K	3
Losartan 50mgx1200 comp. be po 10277	$150.0K	3
Amlodipino 5 MG 100 x	$142.4K	3
Diclofenaco sodico 100mgx8 cap lp	$138.7K	4
Lactulose solution USP 200ML x 24	$127.3K	3
Ibuprofen oral suspension 100MG/5ML	$126.9K	6
Domperidona 10 with be logo 50x10t rm domperidone b	$119.8K	4
Sertralina 50MG x 500 comp be sertraline tablets 50 MG mfg lic no mh drugs 25 kd 276 packing 50 x 10	$116.7K	3
Losartan 50mgx1200 comp be po 10268 losartan potassium tablets 50 MG b no fw3c051 fw3c054 mfg mar 23 exp feb 26 mh	$100.0K	2
Losartan 50mgx1200 comp. be po 10276	$100.0K	2
Amoxicilina + ac.clav.875/125 x14 comp.	$100.0K	2

Opko Chile S.a., imports 235 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Losartan	Cardiovascular	$7.7M	153	1.7%	5
2	Enalapril	Cardiovascular	$1.1M	42	0.5%	6
3	Lactulose	Gastrointestinal	$1.0M	36	4.4%	2
4	Domperidone	Gastrointestinal	$550.0K	11	1.9%	5
5	Ambroxol	Respiratory & OTC	$476.8K	33	3.2%	6
6	Bromhexine	Respiratory & OTC	$261.7K	18	1.6%	7
7	Melatonin	Nutritional Supplements	$100.0K	2	1.1%	14

Opko Chile S.a., imports 7 pharmaceutical products across 4 categories into Chile totaling $11.2M.

Opko Chile S.a., — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Opko Chile S.A. is a Chilean pharmaceutical company specializing in the importation, commercialization, and distribution of finished pharmaceutical formulations. Established on October 7, 2009, it operates as a subsidiary of OPKO Health, Inc., a U.S.-based multinational pharmaceutical and diagnostics company headquartered in Miami, Florida. The acquisition of Pharma Genexx S.A. by OPKO Health marked the inception of Opko Chile S.A., expanding OPKO's presence in the Latin American market.

Headquartered in Santiago, Chile, Opko Chile S.A. focuses on the development, production, and commercialization of pharmaceutical products and medical supplies. Its product portfolio encompasses a wide range of therapeutic areas, including cardiovascular, gastrointestinal, respiratory, and over-the-counter (OTC) products. The company serves both public and private institutions, including government entities like the National Health Service (CENABAST), independent pharmacies, and major pharmacy chains, ensuring nationwide distribution through its dedicated sales force. (getonbrd.cl)

2Distribution Network

Opko Chile S.A. maintains its primary office at Agustinas 640, 10th floor, in the Metropolitan Region of Santiago. While specific details about its warehouse locations and logistics capabilities are not publicly disclosed, the company is known to have a nationwide distribution network. This extensive coverage enables Opko Chile S.A. to effectively supply pharmaceutical products across Chile, catering to both urban and rural regions. The company's logistics infrastructure is designed to ensure timely and efficient delivery of products to various stakeholders, including hospitals, pharmacies, and government institutions. (getonbrd.cl)

3Industry Role

In Chile's pharmaceutical supply chain, Opko Chile S.A. functions primarily as an importer and distributor of finished pharmaceutical formulations. The company sources a diverse range of products from international suppliers, including Indian manufacturers, and is responsible for their commercialization and distribution within the Chilean market. By importing and distributing these products, Opko Chile S.A. plays a crucial role in ensuring the availability of essential medications across the country, thereby contributing to the overall healthcare infrastructure. (getonbrd.cl)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Opko Chile S.a.,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Opko Chile S.A. demonstrates a significant concentration in its sourcing strategy, with a total import value of $11.2 million USD from India over 295 shipments. The top five imported products—Losartan, Enalapril, Lactulose, Domperidone, and Ambroxol—account for 96.8% of the total import value, indicating a high degree of portfolio concentration. This sourcing pattern suggests a strategic focus on specific therapeutic areas, particularly cardiovascular and gastrointestinal treatments. The reliance on a limited number of products may streamline operations and strengthen supplier relationships but also exposes the company to risks associated with market fluctuations and regulatory changes affecting these specific products.

The shipment data reveals a stable relationship with Indian suppliers, with the top supplier, EMIL Pharmaceutical Industries Private Limited, accounting for 53.6% of the total import value. This indicates a strong and ongoing partnership, which can lead to favorable terms and consistent product quality. However, the high concentration on a few suppliers and products may pose challenges if there are disruptions in supply chains or changes in regulatory environments.

2Supply Chain Resilience

Opko Chile S.A.'s supply chain resilience is closely tied to its sourcing strategy from Indian suppliers. The company's dependence on a limited number of suppliers and products suggests a streamlined procurement process but also highlights potential vulnerabilities. The absence of publicly available information regarding backup suppliers and the diversity of formulations imported indicates a need for strategic planning to mitigate risks associated with supply chain disruptions. Ensuring compliance with international Good Manufacturing Practice (GMP) standards and maintaining strong relationships with key suppliers are essential for sustaining supply chain stability.

Importing Pharmaceuticals into Chile — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Chile

1Regulatory Authority & Framework

In Chile, the regulatory authority responsible for the control of pharmaceutical products, including biologicals and medical devices, is the Public Health Institute (Instituto de Salud Pública, ISP). The ISP operates under the Ministry of Health (MINSAL) and oversees regulations governing the import, clearance, export, production, and manufacturing of pharmaceutical products and medical devices. The Ministry of Health is responsible for defining and controlling these regulations, ensuring that imported pharmaceutical products meet the required standards for safety, efficacy, and quality. (britcham.cl)

Key legislation governing pharmaceutical imports into Chile includes the Health Code (Código Sanitario) and the Pharmaceutical Regulations (Reglamento Sanitario de los Alimentos). These regulations outline the requirements for product registration, labeling, advertising, and distribution. The ISP is responsible for enforcing these regulations, ensuring that all pharmaceutical products imported into Chile comply with the established standards. (britcham.cl)

2Import Licensing & GMP

Import licensing requirements in Chile stipulate that pharmaceutical products must be registered with the ISP before they can be imported and marketed. The registration process involves submitting detailed information about the product, including its composition, intended use, packaging, labeling, and manufacturer information. Importers must also comply with specific requirements regarding the storage, transportation, and distribution of pharmaceutical products to ensure their quality, safety, and efficacy.

Opko Chile S.a., — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Opko Chile S.A.'s product category focus on cardiovascular (78.2%), gastrointestinal (14.3%), and respiratory & OTC (6.6%) products aligns with the therapeutic areas of its top imported products: Losartan, Enalapril, Lactulose, Domperidone, and Ambroxol. This strategic focus is driven by market demand for treatments in these areas, addressing prevalent health conditions in Chile. By concentrating on these therapeutic categories, Opko Chile S.A. aims to meet the needs of both public and private healthcare sectors, ensuring the availability of essential medications.

2Sourcing Profile

Opko Chile S.A. primarily sources generic pharmaceutical products from India, with a total import value of $11.2 million USD over 295 shipments. The company's sourcing strategy emphasizes finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. This approach allows Opko Chile S.A. to offer a diverse range of products to the Chilean market, catering to various therapeutic needs. India's established pharmaceutical manufacturing industry, known for its adherence to international GMP standards, makes it a reliable source for these products.

3Market Positioning

Frequently Asked Questions — Opko Chile S.a.,

What products does Opko Chile S.a., import from India?

Opko Chile S.a., imports 7 pharmaceutical products across 4 categories. Top imports: Losartan ($7.7M), Enalapril ($1.1M), Lactulose ($1.0M), Domperidone ($550.0K), Ambroxol ($476.8K).

Who supplies pharmaceuticals to Opko Chile S.a., from India?

Opko Chile S.a., sources from 11 verified Indian suppliers. The primary supplier is Emil Pharmaceutical Industries Private Limited (53.6% of imports, $5.3M).

What is Opko Chile S.a.,'s total pharmaceutical import value?

Opko Chile S.a.,'s total pharmaceutical import value from India is $11.2M, based on 295 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Opko Chile S.a., focus on?

Opko Chile S.a., imports across 4 categories. The largest: Cardiovascular (78.2%), Gastrointestinal (14.3%), Respiratory & OTC (6.6%).

Get Full Opko Chile S.a., Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 4 company name variants from customs records. For current shipment-level data, contact TransData Nexus.